290 related articles for article (PubMed ID: 19297407)
1. Tuberous sclerosis complex, implication from a rare genetic disease to common cancer treatment.
Inoki K; Guan KL
Hum Mol Genet; 2009 Apr; 18(R1):R94-100. PubMed ID: 19297407
[TBL] [Abstract][Full Text] [Related]
2. Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb.
Tee AR; Manning BD; Roux PP; Cantley LC; Blenis J
Curr Biol; 2003 Aug; 13(15):1259-68. PubMed ID: 12906785
[TBL] [Abstract][Full Text] [Related]
3. Upregulation of 6-phosphofructo-2-kinase (PFKFB3) by hyperactivated mammalian target of rapamycin complex 1 is critical for tumor growth in tuberous sclerosis complex.
Wang Y; Tang S; Wu Y; Wan X; Zhou M; Li H; Zha X
IUBMB Life; 2020 May; 72(5):965-977. PubMed ID: 31958214
[TBL] [Abstract][Full Text] [Related]
4. Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling.
Tee AR; Fingar DC; Manning BD; Kwiatkowski DJ; Cantley LC; Blenis J
Proc Natl Acad Sci U S A; 2002 Oct; 99(21):13571-6. PubMed ID: 12271141
[TBL] [Abstract][Full Text] [Related]
5. Mourning Dr. Alfred G. Knudson: the two-hit hypothesis, tumor suppressor genes, and the tuberous sclerosis complex.
Hino O; Kobayashi T
Cancer Sci; 2017 Jan; 108(1):5-11. PubMed ID: 27862655
[TBL] [Abstract][Full Text] [Related]
6. Tsc2 gene inactivation causes a more severe epilepsy phenotype than Tsc1 inactivation in a mouse model of tuberous sclerosis complex.
Zeng LH; Rensing NR; Zhang B; Gutmann DH; Gambello MJ; Wong M
Hum Mol Genet; 2011 Feb; 20(3):445-54. PubMed ID: 21062901
[TBL] [Abstract][Full Text] [Related]
7. The tuberous sclerosis complex genes in tumor development.
Mak BC; Yeung RS
Cancer Invest; 2004; 22(4):588-603. PubMed ID: 15565817
[TBL] [Abstract][Full Text] [Related]
8. Structure of the Tuberous Sclerosis Complex 2 (TSC2) N Terminus Provides Insight into Complex Assembly and Tuberous Sclerosis Pathogenesis.
Zech R; Kiontke S; Mueller U; Oeckinghaus A; Kümmel D
J Biol Chem; 2016 Sep; 291(38):20008-20. PubMed ID: 27493206
[TBL] [Abstract][Full Text] [Related]
9. Translatome analysis of tuberous sclerosis complex 1 patient-derived neural progenitor cells reveals rapamycin-dependent and independent alterations.
Aksoylu IS; Martin P; Robert F; Szkop KJ; Redmond NE; Bhattacharyya S; Wang J; Chen S; Beauchamp RL; Nobeli I; Pelletier J; Larsson O; Ramesh V
Mol Autism; 2023 Oct; 14(1):39. PubMed ID: 37880800
[TBL] [Abstract][Full Text] [Related]
10. Tuberin and hamartin are aberrantly expressed and linked to clinical outcome in human breast cancer: the role of promoter methylation of TSC genes.
Jiang WG; Sampson J; Martin TA; Lee-Jones L; Watkins G; Douglas-Jones A; Mokbel K; Mansel RE
Eur J Cancer; 2005 Jul; 41(11):1628-36. PubMed ID: 15951164
[TBL] [Abstract][Full Text] [Related]
11. Evidence for separable functions of tuberous sclerosis gene products in mammalian cell cycle regulation.
Miloloza A; Kubista M; Rosner M; Hengstschläger M
J Neuropathol Exp Neurol; 2002 Feb; 61(2):154-63. PubMed ID: 11853018
[TBL] [Abstract][Full Text] [Related]
12. Interaction between hamartin and tuberin, the TSC1 and TSC2 gene products.
van Slegtenhorst M; Nellist M; Nagelkerken B; Cheadle J; Snell R; van den Ouweland A; Reuser A; Sampson J; Halley D; van der Sluijs P
Hum Mol Genet; 1998 Jun; 7(6):1053-7. PubMed ID: 9580671
[TBL] [Abstract][Full Text] [Related]
13. Loss of the tuberous sclerosis complex protein tuberin causes Purkinje cell degeneration.
Reith RM; Way S; McKenna J; Haines K; Gambello MJ
Neurobiol Dis; 2011 Jul; 43(1):113-22. PubMed ID: 21419848
[TBL] [Abstract][Full Text] [Related]
14. TSC2 missense mutations inhibit tuberin phosphorylation and prevent formation of the tuberin-hamartin complex.
Nellist M; Verhaaf B; Goedbloed MA; Reuser AJ; van den Ouweland AM; Halley DJ
Hum Mol Genet; 2001 Dec; 10(25):2889-98. PubMed ID: 11741832
[TBL] [Abstract][Full Text] [Related]
15. Functional characterisation of the TSC1-TSC2 complex to assess multiple TSC2 variants identified in single families affected by tuberous sclerosis complex.
Nellist M; Sancak O; Goedbloed M; Adriaans A; Wessels M; Maat-Kievit A; Baars M; Dommering C; van den Ouweland A; Halley D
BMC Med Genet; 2008 Feb; 9():10. PubMed ID: 18302728
[TBL] [Abstract][Full Text] [Related]
16. mTORC1 enhancement of STIM1-mediated store-operated Ca2+ entry constrains tuberous sclerosis complex-related tumor development.
Peng H; Liu J; Sun Q; Chen R; Wang Y; Duan J; Li C; Li B; Jing Y; Chen X; Mao Q; Xu KF; Walker CL; Li J; Wang J; Zhang H
Oncogene; 2013 Sep; 32(39):4702-11. PubMed ID: 23108404
[TBL] [Abstract][Full Text] [Related]
17. Pathogenesis of tuberous sclerosis subependymal giant cell astrocytomas: biallelic inactivation of TSC1 or TSC2 leads to mTOR activation.
Chan JA; Zhang H; Roberts PS; Jozwiak S; Wieslawa G; Lewin-Kowalik J; Kotulska K; Kwiatkowski DJ
J Neuropathol Exp Neurol; 2004 Dec; 63(12):1236-42. PubMed ID: 15624760
[TBL] [Abstract][Full Text] [Related]
18. Renal disease in tuberous sclerosis complex: pathogenesis and therapy.
Lam HC; Siroky BJ; Henske EP
Nat Rev Nephrol; 2018 Nov; 14(11):704-716. PubMed ID: 30232410
[TBL] [Abstract][Full Text] [Related]
19. Prolonging the survival of Tsc2 conditional knockout mice by glutamine supplementation.
Rozas NS; Redell JB; McKenna J; Moore AN; Gambello MJ; Dash PK
Biochem Biophys Res Commun; 2015 Feb; 457(4):635-9. PubMed ID: 25613864
[TBL] [Abstract][Full Text] [Related]
20. Signaling events downstream of mammalian target of rapamycin complex 2 are attenuated in cells and tumors deficient for the tuberous sclerosis complex tumor suppressors.
Huang J; Wu S; Wu CL; Manning BD
Cancer Res; 2009 Aug; 69(15):6107-14. PubMed ID: 19602587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
